Description: Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Home Page: www.claritypharmaceuticals.com
CU6 Technical Analysis
National Innovation Centre
Sydney,
NSW
2015
Australia
Phone:
61 2 9209 4037
Officers
| Name | Title |
|---|---|
| Dr. Alan John Taylor Ph.D. | Exec. Chairman |
| Dr. Colin David Biggin Ph.D. | MD, CEO & Exec. Director |
| Mr. David K. Green BEc., CA | Chief Financial Officer |
| Mr. Robert Vickery | Company Sec. |
| Dr. Michael D. Ironside | Director of Operations |
| Dr. Jeffrey Norenberg | Chief Scientific Officer |
| Dr. Ellen van Dam Ph.D. | Head of R&D |
| Mr. Shaemus Gleason | Exec. VP of US Operations |
| Dr. Robert M. Miller Ph.D. | Consultant Chief Medical Officer |
| Mr. William Cheadle | Financial Controller |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7448 |
| Price-to-Sales TTM: | 38.334 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |